# Pilin Genotyping for Group A Streptococci

> **NIH NIH R03** · NEW YORK MEDICAL COLLEGE · 2020 · $83,280

## Abstract

PROJECT SUMMARY
Group A Streptococcus (GAS) is a human pathogen of global importance that primarily infects the throat
(pharyngitis) or skin (impetigo), leading to ~750 million infections per year; high rates of morbidity and mortality
are due to invasive disease and autoimmune complications. Despite its importance as a global pathogen, there
is no vaccine available for the prevention of GAS disease.
The global GAS population is highly diverse, due in large part to the high degree of antigenic heterogeneity
among cell surface proteins. Diversity is amplified via the extensive horizontal gene transfer that characterizes
this species to yield numerous unique combinations of surface protein antigens. Yet, a biologically relevant and
standardized definition for GAS “strain” is lacking. Historically, two serological typing schemes (M and T) were
used to characterize GAS strains: M-typing is based on the short M protein surface fibril, and T-typing is based
on thin elongated pili. In addition to high sequence diversity, the M protein and pili act as key virulence factors
and are targets of host protective immunity. M-typing has been supplanted by emm genotyping. The proposed
project seeks to develop a sequence-based typing scheme for GAS pili (i.e., T-antigens).
The Specific Aim seeks to develop a pilin genotyping scheme based on adhesin and backbone pilin genes.
Genome sequences from a global and diverse collection of GAS isolates are the source material for the initial
database of pilin genes; sequences will undergo phylogenetic analysis and assignment to clusters. Data will be
curated and made publicly available on www.pubmlst.org, a user-friendly website. Pilin type will be combined
with emm type and MLST-defined sequence type to yield a definition for GAS “strain.”
The proposed work will provide an improved molecular epidemiology typing scheme for this major global
pathogen. Standardization of nomenclature can facilitate “strain” comparisons in the GAS field and enable
rapid recognition of newly emerged strains. Pilin typing will also provide a foundation for future work leading to
new hypotheses that address the molecular basis for pathogenesis of different types of GAS disease, and the
genetic basis for new strain emergence and immune escape. The enriched molecular epidemiology data can
also promote rational approaches to vaccine design and vaccination strategies. Progress towards elucidating
the molecular mechanisms of pathogenesis and developing a GAS vaccine are long-term goals.

## Key facts

- **NIH application ID:** 10056809
- **Project number:** 1R03AI148983-01A1
- **Recipient organization:** NEW YORK MEDICAL COLLEGE
- **Principal Investigator:** Debra E BESSEN
- **Activity code:** R03 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $83,280
- **Award type:** 1
- **Project period:** 2020-06-01 → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10056809

## Citation

> US National Institutes of Health, RePORTER application 10056809, Pilin Genotyping for Group A Streptococci (1R03AI148983-01A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10056809. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*